Catarina M. Azevedo

Catarina M. Azevedo

Auto-generated profile, based on publicly available information

Catarina M. Azevedo

Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2022 in FEBS Letters
Verified
Journal Article
Closed access
IAInês Alves
Inês Alves
ÂFÂngela Fernandes
Ângela Fernandes
BSBeatriz Santos‐Pereira
Beatriz Santos‐Pereira
CACatarina M. Azevedo
Catarina M. Azevedo
SPSalomé Pinho
Salomé Pinho

19 August 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CACatarina M. Azevedo
Catarina M. Azevedo
BXBingxian Xie
Bingxian Xie
WGWilliam G. Gunn
William G. Gunn
RPRonal M. Peralta
Ronal M. Peralta
CDCarolina S. Dantas
Carolina S. Dantas
SPSalomé Pinho
Salomé Pinho
T-cell therapies have transformed cancer treatment. Although surface glycans have been shown to play critical roles in regulating T-cell development and function, whether and how the glycome influences T cell–mediated tumor immunity remains an area of active investigation. In this study, we show that the intratumoral T-cell glycome is altered early in human colorectal cancer, with substantial changes in branched N-glycans. We demonstrated that CD8+ T cells expressing β1,6-GlcNAc–branched N-glycans adopted an exhausted phenotype, marked by increased PD1 and Tim3 expression. CRISPR-Cas9 deletion of key branching glycosyltransferase genes revealed that Mgat5 played a prominent role in T-cell exhaustion. In culture-based assays and tumor studies, Mgat5 deletion in CD8+ T cells resulted in improved cancer cell killing. These findings prompted the assessment of whether MGAT5 deletion in anti-CD19 chimeric antigen receptor (CAR) T cells could enable this therapeutic modality in a solid tumor setting. We showed that MGAT5 knockout anti-CD19–CAR T cells inhibited the growth of CD19-transduced tumors. Together, these findings show that MGAT5-mediated branched N-glycans regulate CD8+ T-cell function in cancer and provide a strategy to enhance the antitumor activity of native and CAR T cells.

1 October 2025
Verified
Other
Open access
CACatarina M. Azevedo
Catarina M. Azevedo
BXBingxian Xie
Bingxian Xie
WGWilliam G. Gunn
William G. Gunn
RPRonal M. Peralta
Ronal M. Peralta
CDCarolina S. Dantas
Carolina S. Dantas
SPSalomé Pinho
Salomé Pinho
T-cell therapies have transformed cancer treatment. Although surface glycans have been shown to play critical roles in regulating T-cell development and function, whether and how the glycome influences T cell–mediated tumor immunity remains an area of active investigation. In this study, we show that the intratumoral T-cell glycome is altered early in human colorectal cancer, with substantial changes in branched N-glycans. We demonstrated that CD8+ T cells expressing β1,6-GlcNAc–branched N-glycans adopted an exhausted phenotype, marked by increased PD1 and Tim3 expression. CRISPR-Cas9 deletion of key branching glycosyltransferase genes revealed that Mgat5 played a prominent role in T-cell exhaustion. In culture-based assays and tumor studies, Mgat5 deletion in CD8+ T cells resulted in improved cancer cell killing. These findings prompted the assessment of whether MGAT5 deletion in anti-CD19 chimeric antigen receptor (CAR) T cells could enable this therapeutic modality in a solid tumor setting. We showed that MGAT5 knockout anti-CD19–CAR T cells inhibited the growth of CD19-transduced tumors. Together, these findings show that MGAT5-mediated branched N-glycans regulate CD8+ T-cell function in cancer and provide a strategy to enhance the antitumor activity of native and CAR T cells.